People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kura Oncology, Inc. | — | Biotechnology | Series D+ | $241.7M | $1.9B | 2015 |
| Perspective Therapeutics, Inc. | — | Biotechnology | Series C | $163.6M | $882.9M | 2024 |
| PepGen Inc. | — | Biotechnology | Series D+ | $126.9M | $3.2B | 2021 |
| Kura Operations, Inc. | — | Biotechnology | Series C | $63.4M | $2.5B | 2015 |
| Araxes Pharma, LLC | — | Pharmaceuticals | Seed | $1.0M | $39.6M | 2012 |
HEIDI HENSON at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside HEIDI HENSON on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| TROY WILSON | 3 | 7 |
| YI LIU | 2 | 4 |
| PINGDA REN | 2 | 3 |
| ANTONIO GUALBERTO | 2 | 2 |
| ANNETTE NORTH | 2 | 2 |
| Joshua Resnick | 1 | 12 |
| Josh Resnick | 1 | 7 |
| Matthew Wood | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| Johan (Thijs) Spoor | 1 | 4 |
| Michael McCormick | 1 | 4 |
| Ramin Farzaneh-Far | 1 | 3 |
| Mary Szela | 1 | 3 |
| Teresa Bair | 1 | 2 |
| Mark J. Austin | 1 | 2 |
| Michael W. McCormick | 1 | 2 |
| DIANE PARKS | 1 | 2 |
| Jonathan Hunt | 1 | 2 |
| THOMAS MALLEY | 1 | 2 |
| KATHLEEN FORD | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.